SEC EDGARSep 14$HTFL

Farquhar John C.M. sold $1.8M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at an average of $46.78 ($46.42–$50.00, $1.82M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farquhar John C.M.

Published Sep 14, 2026, 10:41 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 14, 2026, 10:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

medium confidence

Mentioned

$HTFL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short-term traders.

Market read

First public disclosure of a CEO stock sale; modest relevance for traders monitoring insider activity.

What to watch

CEO may be diversifying holdings; no immediate change in company fundamentals.

Relevance 5/10Novelty 5/10Timing: filed Sep 14 2026

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishMedium confidence

Context

CEO John Farquhar sold 38,900 shares for $1.8M via a 10b5-1 plan, reducing his stake to 321,914 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Sale size is modest relative to market cap, but CEO involvement adds weight.

Market effects

Sector

Minimal impact on the broader medtech sector.

Regional

Limited to US-listed medtech investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine 10b5-1 execution, not a bearish signal.

Key entities

Company
Heartflow, Inc.
US-listed medical device company (NASDAQ: HTFL).
Person
John C.M. Farquhar
Chief Executive Officer of Heartflow.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.